Mouse intestinal microbiome modulation by oral administration of a GABA-producing Bifidobacterium adolescentis strain.
Microbiol Spectr
; 12(1): e0258023, 2024 Jan 11.
Article
em En
| MEDLINE
| ID: mdl-37991375
ABSTRACT
IMPORTANCE The gut microbiome-brain communication signaling has emerged in recent years as a novel target for intervention with the potential to ameliorate some conditions associated with the central nervous system. Hence, probiotics with capacity to produce neurotransmitters, for instance, have come up as appealing alternatives to treat disorders associated with disbalanced neurotransmitters. Herein, we further deep into the effects of administering a gamma-aminobutyric acid (GABA)-producing Bifidobacterium strain, previously demonstrated to contribute to reduce serum glutamate levels, in the gut microbiome composition and metabolic activity in a mouse model. Our results demonstrate that the GABA-producing strain administration results in a specific pattern of gut microbiota modulation, different from the one observed in animals receiving non-GABA-producing strains. This opens new avenues to delineate the specific mechanisms by which IPLA60004 administration contributes to reducing serum glutamate levels and to ascertain whether this effect could exert health benefits in patients of diseases associated with high-glutamate serum concentrations.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Probióticos
/
Microbioma Gastrointestinal
/
Bifidobacterium adolescentis
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article